Telix Pharmaceuticals Limited TLX

The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation for the Company's BiPASS® program.

Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful stakes in fast growing outfits, incentives to grow carefully rather than chase cheap debt can be stronger. This article walks through three high growth, high insider ownership stocks from that group. The three stocks below are a small sample, and the full...

Telix Pharmaceuticals has delivered a very strong 185.1% share price gain over the past five years, yet the latest acquisition plans and product approvals leave a clear question about whether that journey is still backed by its cash flows. With the stock now trading around A$16.08 after a weaker recent patch, investors are increasingly focused on what the underlying cash generation can reasonably support. That 185.1% return over five years puts real weight on whether Telix’s current...

Telix Pharmaceuticals (ASX:TLX) has moved to lead a merger with ITM Isotope Technologies Munich SE, a radioisotope producer and radiopharmaceutical developer, in a transaction valued at up to A$2.35b. Telix Pharmaceuticals shares trade at A$16.08 after a sharp 1 day share price decline of 4.23% and a 7 day share price fall of 4.68% following the merger announcement. However, the year to date share price return of 41.55% and 5 year total shareholder return of 185.11% suggest longer term...

Telix Pharmaceuticals Limited (NASDAQ:TLX) agreed on September 21 to acquire ITM Isotope Technologies Munich SE. The deal is worth up to $2.35 billion. Telix will pay $1.65 billion upfront, before cash and debt. A further $700 million follows if ITM’s lead drug wins approval and hits sales targets. Telix is paying mostly in its own […]

Telix Pharmaceuticals (ASX: TLX) has agreed to acquire ITM Isotope Technologies Munich SE in a deal valued at US$2.35b. The transaction gives Telix control of a major global producer of medical radioisotopes used in cancer diagnosis and treatment. Management describes the purchase as a step toward a vertically integrated radiopharmaceutical model with broader manufacturing and commercial reach. The ITM Isotope Technologies Munich acquisition could reshape Telix's business profile, but...

Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts.

Telix Pharmaceuticals (TLX) agreed to acquire Germany-based ITM Isotope Technologies Munich in a dea

The deal is expected to close by the end of the 2026 financial year, subject to Telix shareholder and regulatory approvals.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE ("ITM"), a global leader in radioisotope production and radiopharmaceutical development.

The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceutical therapies. Oncology leads adoption, while therapeutic agents and radiotheranostics are key growth segments. North America holds the largest market share, with Asia-Pacific forecast to grow fastest. The report analyses market trends, technologies, applications, regional opportunities and leading companies, in

Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients.FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines®.Pixclara expands Telix’s industry-leading Precision Medicine business and reinforces the Company’s leadership in diagnostics and targete

MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference, both in New York, NY. Presentation details: Morgan Stanley 24th Annual Global Healthcare Co

The FDA’s target date for deciding on Pixclara is September 11.

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th

Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose 5. 3% in premarket trading on Wednesday as investors assessed the company’s Phase 3 BiPASS trial progress and its regulatory pathway in the U.